Chitosan-Coated Silver Nanourchins for Imatinib Mesylate Delivery: Biophysical Characterization, In-Silico Profiling, and Anti-Colon Cancer Efficacy DOI
Sankha Bhattacharya,

Aalind Joshi,

Vishal Beldar

et al.

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 21, 2025

This study investigates the synthesis and characterization of silver nanourchins coated with chitosan (IMT-CS-AgNUs) as a novel platform for delivery imatinib mesylate (IMT) treatment colon cancer. In-silico analysis discovered 10 key metabolites IMT, which have associated respiratory neurotoxic risks. Molecular docking studies showed high affinity binding IMT to critical proteins, including BCL2 (−6.637 kcal/mol), Caspase-6, EGFR, proved its potential therapeutic value. IMT-CS-AgNUs were prepared by ionic gelation, nanoparticles had size 192.98 nm, an entrapment efficiency 85.7%. The FTIR XRD structural confirmed that nanocarriers stable amorphous in nature. In vitro HCT116 cells significantly increased cytotoxicity IC50 0.4 μg/mL; apoptosis 42.5% ROS generation 47.8% when compared only IMT. release drugs from was sustained over 85% 60 h, selectively inhibited pathogenic bacteria without harming beneficial microbes, antiangiogenic activity, is validated through HET-CAM assay. Gene expression analyses there marked downregulation upregulation apoptotic genes. Pharmacokinetic Wistar rats improved bioavailability 1.8, allows targeted drug concentrations lessened systemic toxicity. Thus, development represents potent approach therapy against cancer, providing efficacy, controlled release, added safety.

Language: Английский

Chitosan-Coated Silver Nanourchins for Imatinib Mesylate Delivery: Biophysical Characterization, In-Silico Profiling, and Anti-Colon Cancer Efficacy DOI
Sankha Bhattacharya,

Aalind Joshi,

Vishal Beldar

et al.

Molecular Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 21, 2025

This study investigates the synthesis and characterization of silver nanourchins coated with chitosan (IMT-CS-AgNUs) as a novel platform for delivery imatinib mesylate (IMT) treatment colon cancer. In-silico analysis discovered 10 key metabolites IMT, which have associated respiratory neurotoxic risks. Molecular docking studies showed high affinity binding IMT to critical proteins, including BCL2 (−6.637 kcal/mol), Caspase-6, EGFR, proved its potential therapeutic value. IMT-CS-AgNUs were prepared by ionic gelation, nanoparticles had size 192.98 nm, an entrapment efficiency 85.7%. The FTIR XRD structural confirmed that nanocarriers stable amorphous in nature. In vitro HCT116 cells significantly increased cytotoxicity IC50 0.4 μg/mL; apoptosis 42.5% ROS generation 47.8% when compared only IMT. release drugs from was sustained over 85% 60 h, selectively inhibited pathogenic bacteria without harming beneficial microbes, antiangiogenic activity, is validated through HET-CAM assay. Gene expression analyses there marked downregulation upregulation apoptotic genes. Pharmacokinetic Wistar rats improved bioavailability 1.8, allows targeted drug concentrations lessened systemic toxicity. Thus, development represents potent approach therapy against cancer, providing efficacy, controlled release, added safety.

Language: Английский

Citations

0